State Street’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

State Street’s Portfolio KRSA Stock Details KRSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-824	Closed	-$50.1K	–	4688
2023 Q1	$50.1K	Hold	824	–	–	﹤0.01%	4502
2022 Q4	$75.7K	Hold	824	–	–	﹤0.01%	4448
2022 Q3	$99K	Hold	824	–	–	﹤0.01%	4467
2022 Q2	$63K	Sell	824 -1	-0.1%	-$14	﹤0.01%	4673
2022 Q1	$128K	Buy	825 +33	+4%	+$795	﹤0.01%	4558
2021 Q4	$191K	Buy	792 +151	+24%	+$7.13K	﹤0.01%	4373
2021 Q3	$275K	Buy	641 +46	+8%	+$3.01K	﹤0.01%	4233
2021 Q2	$325K	Sell	595 -2,263	-79%	-$142K	﹤0.01%	4022
2021 Q1	$1.12M	Sell	2,858 -194	-6%	-$14.6K	﹤0.01%	3599
2020 Q4	$1.31M	Sell	3,052 -84	-3%	-$5.73K	﹤0.01%	3508
2020 Q3	$2.67M	Sell	3,136 -436	-12%	-$49.9K	﹤0.01%	3084
2020 Q2	$2.96M	Sell	3,572 -266	-7%	-$22.2K	﹤0.01%	3020
2020 Q1	$1.42M	Buy	3,838 +76	+2%	+$5.42K	﹤0.01%	3199
2019 Q4	$1.43M	Buy	3,762 +526	+16%	+$49.1K	﹤0.01%	3341
2019 Q3	$5.49M	Buy	3,236 +185	+6%	+$40K	﹤0.01%	2739
2019 Q2	$4.89M	Buy	+3,051	New	+$863K	﹤0.01%	2832

Other funds holding KRSA

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street's KRSA Position: Q2 2023 in Review

State Street sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q2 2023, closing a stake of 824 shares — an estimated $50.1K sold.

State Street first reported a position in KRSA in Q2 2019 and held it in 16 quarters. The position peaked at $5.49M in Q3 2019. 17 funds tracked by Wall St. Rank hold KRSA as of Q2 2023.

State Street reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
State Street sold 824 Korsana Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $50.1K.
State Street first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 16 quarters.
State Street's Korsana Biosciences, Inc. Common Stock position peaked at $5.49M in Q3 2019.
17 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q2 2023.

Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.